To assess the effectiveness of different antibiotics in lung and blood infections caused by carbapenem resistant bacteria
- Conditions
- Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms
- Registration Number
- CTRI/2024/02/062846
- Lead Sponsor
- Dr Deepak Govil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Adult more than 18 years of age with confirmed culture based diagnosis of hospital acquired pneumonia (HAP) (pneumonia developing at least 48 hours after hospital admission) and / or blood stream infection caused by CRE (Klebsiella pneumoniae, Escherichia coli) CRAB & CRPA
Received antibiotic mono and or combination therapy for at-least 48 hours as per clinician’s discretion
Culture positive from any site other than blood stream/ pneumonia.
Any organism other than CRE (Klebsiella pneumoniae, Escherichia coli), CRAB & CRPA isolated within 14 days of initiation/ EOT of antibiotic therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Clinical outcomes of patient with BSI <br/ ><br>2.Clinical outcomes of patient with HAP <br/ ><br>3.Clinical outcomes of patient with HAP plus BSI <br/ ><br>4.Microbiological outcome in patients with BSI <br/ ><br>5.Microbiological outcome in patients with HAP <br/ ><br>6.Microbiological outcome in patients with HAP plus BSITimepoint: Day 7 and day 14 or EOT from the initiation of antibiotic mono-/ combination therapy <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Duration of invasive mechanical ventilation (hours) <br/ ><br>2.Duration of vasopressor requirement (hours) <br/ ><br>3.Need for RRT (Yes/No) <br/ ><br>4.Length of hospital stay <br/ ><br>5.Length of ICU stay <br/ ><br>6.ICU outcome <br/ ><br>7.Hospital outcome <br/ ><br>Timepoint: 7 days and 14 days or end of treatment